Gefitinib in cervical cancer
Phase 3
- Conditions
- Health Condition 1: null- Cervical cancer stage II to III
- Registration Number
- CTRI/2017/12/010726
- Lead Sponsor
- Mysore medical college ad research institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other (Terminated)
- Sex
- Not specified
- Target Recruitment
- 23
Inclusion Criteria
1. FIGO stage II to III cervical cancer.
2. Histopathologically proven cervical cancer.
3. Serum creatinine < 1.4mg/dl.
Exclusion Criteria
1. Pregnant and breast feeding patients.
2. Immunocompromised patients and with Human
immunodeficient virsu (HIV) infection.
3. Any allergy to Cisplatin and Gefitinib.
4. Prior surgery for cervical cancer.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the response rate with the addition of Gefitinib in cervical cancer patients receiving chemoradiation.Timepoint: at the end of 6 months
- Secondary Outcome Measures
Name Time Method To evaluate the toxicity during the treatmentTimepoint: during the treatment and post treatment at 6 months